Biological agents in management of osteoporosis (Q38247465)

1 September 2017

1 reference

title

Biological agents in management of osteoporosis (English)

1 reference

1 September 2017

0 references

Sri Harsha Tella

1

1 reference

PubMed ID

25204309

1 September 2017

J Christopher Gallagher

series ordinal

2

1 reference

1 September 2017

11 September 2014

1 reference

European Journal of Clinical Pharmacology

1 September 2017

1 reference

1 September 2017

70

1 reference

1 September 2017

11

1 reference

1 September 2017

1291-1301

1 reference

https://scigraph.springernature.com/pub.10.1007/s00228-014-1735-5

1 September 2017

0 references

cites work

Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

WNT signaling in bone homeostasis and disease: from human mutations to treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Sclerostin: current knowledge and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

A single-dose study of denosumab in patients with various degrees of renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Characterization of the Structural Features and Interactions of Sclerostin: MOLECULAR INSIGHT INTO A KEY REGULATOR OF Wnt-MEDIATED BONE FORMATION

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Romosozumab in postmenopausal women with low bone mineral density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1735-5

Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.

21 January 2018

1 reference

12 December 2020

Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal

1 reference

12 December 2020

Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.

1 reference

12 December 2020

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

1 reference

12 December 2020

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.

1 reference

12 December 2020

Sclerostin antibody treatment enhances metaphyseal bone healing in rats

1 reference

12 December 2020

Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis

1 reference

12 December 2020

Prevention and treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial

1 reference

12 December 2020

Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density

1 reference

12 December 2020

10.1007/S00228-014-1735-5

Identifiers

DOI

1 reference

PubMed ID

25204309

Dimensions Publication ID

1 September 2017

0 references

1 reference

PubMed ID

25204309